Table 2.

Novel selective lymphocyte trafficking inhibitors

Selective lymphocyte trafficking inhibitors
Name	Study	UC/Crohns	Mechanism of Action	Authors	Results	Adverse events
Vedolizumab subcutaneous	VISIBLE 1 and 2	Phase III/Phase III	A4b7 inhibitor	Sandborn et al, 202020	UC→ 46.2% of moderate UC patients who responded to IV VDZ sustained remission.	Reaction at injection site
				Vermeire et al, 202218	CD→48% of moderate Crohn’s patients who responded to 2 infusions of VDZ have sustained remission at week 52.
Etrolizumab	HICKORY LAUREL GARDENIA	Phase III/III	Anti- β7 subunit mAb	Peyrin-Biroulet L et al, 2022.22 Vermeire S et al, 2022.23 Danese et al, 202224	UC→Clinical remission (UC patients previously treated with anti-TNF) 18.5% vs 6.3% of placebo at week 14	UC flare, Appendicitis, Anaemia
Carotegrast Methyl (AJM300)		Phase III/-	Anti-a4 mAb (a4b7 and a4b1)	Matsuoka et al, 2022.24	UC→Clinical response in 46% of moderately active UC patients and endoscopic remission in 14% at week 8	Nasopharyngitis

IV, intravenous; UC, ulcerative colitis; VDZ, vedolizumab.